News | October 25, 2023
Sumitomo Pharma announces authorization in Canada of Orgovyx for treatment prostate cancer
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
ASMD is highly variable and the age of onset, specific symptoms and severity of the disorder can vary dramatically from one person to another
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
This inspection is the fourth major regulatory inspection (after Russia, Canada and Brazil), cleared by this site in the past two years
Two-year partnership focused on advocacy, education, and raising awareness of stroke as a global healthcare challenge
NRT offers 50% higher success rate in quitting smoking compared to unassisted attempts
VaxTRIALS Adds a New Latin America Base and Greater Vaccine Research Depth
This integrated care offering is a step forward in our vision of providing an effective continuum of care for patients
The company has received six final approvals that includes Chlorpromazine Hydrochloride Tablets
Subscribe To Our Newsletter & Stay Updated
